Abstract: Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common dose-limiting side effect of many chemotherapeutic drugs, including platinum-based compounds (e.g., cisplatin and oxaliplatin), taxanes (e.g., paclitaxel), vinca alkaloids (e.g., vincristine), and the first-in-class proteasome inhibitor, bortezomib. Among the various sensory symptoms of CIPN, paresthesia, dysesthesia, spontaneous pain, and mechanical and thermal hypersensitivity are prominent. Inflammation, oxidative stress, loss of intraepidermal nerve fibers, modifications of mitochondria, and various ion channels alterations are part of the several mechanisms contributing to CIPN. Because attempts to mitigate chemotherapeutic-induced acute neuronal hyperexcitability and the subsequent peripheral neuropathy have yielded unsatisfactory results, a more in-depth understanding of the mechanism(s) responsible for the neurotoxic action of anticancer drugs is required.
INTRODUCTION
Peripheral neuropathy is an adverse effect common to various chemotherapeutic agents, including vincristine, paclitaxel, oxaliplatin, cisplatin, bortezomib, and thalidomide [1] . Chemotherapy-induced peripheral neuropathy (CIPN) represents a dose-limiting adverse reaction, which negatively affects the quality of life of a relevant part of treated patients and their therapeutic management. The incidence of CIPN is lower in patients treated with a single agent (3-7%), but can rise up to 38% in patients treated with combination regimens [2] . The occurrence and severity of CIPN depend on many factors, including dose intensity, treatment duration, cumulative dose, prior or concurrent treatment with other neurotoxic drugs, and co-existing conditions which give an independent risk of neuropathy, such as diabetes and alcohol abuse.
The platinum-based anticancer drugs cisplatin, carboplatin, and oxaliplatin are successfully used for the treatment of lung, colorectal, ovarian, breast, head and neck, bladder, and testicular cancers. Cisplatin neurotoxicity is predominantly characterized by sensory neuropathy, which principally produces pain and paresthesia in the extremities. This sensory neuropathy may have a delayed onset, appearing weeks after treatment initiation and, in advanced stages, it may progress to severe neuropathic pain and sensory ataxia. The third generation platinum drug oxaliplatin, which is the most active for the treatment of colorectal cancer [3] , shows a dramatic reduction in renal toxicity and ototoxicity [4, 5] , but exhibits a unique neurotoxic profile. Oxaliplatin induces an acute painful neuropathy which appears soon after administration [6] . Patients complain about paresthesia, more often localized periorally and/or to the extremities, and severe cold hypersensitivity. In about 90% of patients, exposure to cold triggers or enhances an acute, transient syndrome characterized by cramps, paresthesia, and dysesthesia. A chronic peripheral neuropathy resembling that linked to cisplatin often develops after multiple treatment cycles with oxaliplatin.
Paclitaxel is a microtubule-targeting agent labeled for the treatment of a wide variety of solid neoplasms currently under investigation to assess its efficacy to treat additional malignant tumors. Paclitaxel-induced neurotoxicity typically presents as a sensory neuropathy with the most common complaints being numbness, tingling, and burning pain. More pronounced symptoms are tingling and allodynia which typically occur in a "glove and stocking" distribution. Sensory symptoms usually start symmetrically in the feet, but also appear simultaneously in both hands and feet [7] . Many cases resolve briefly after paclitaxel discontinuation, but the sensory abnormalities and pain can be long-lasting [8] .
Among other anticancer drugs, the vinca alkaloid vincristine is a widely used antineoplastic agent administered alone or in combination with other drugs in the treatment of many tumor types [9, 10] . Bortezomib is a modified dipeptidyl boronic acid authorized for the treatment of multiple myeloma and mantle cell lymphoma [11] [12] [13] . Recently, thalidomide has received a great deal of attention due to its remarkable therapeutic efficacy in the treatment of multiple myeloma [14] . Vincristine, bortezomib, and thalidomide can also cause CIPN.
Various mechanisms have been suggested to play a role in the development of CIPN and have been explored in rodent models. Different mitochondrial pathways, including regulation of intracellular calcium [15] , generation of reactive oxygen species (ROS) [16] , and apoptotic signaling [17] , have been proposed to contribute to the development of CIPN [18] . Indeed, paclitaxel-evoked painful peripheral neuropathy is associated with increased swollen and vacuolated axonal mitochondria [19] . Moreover, paclitaxel appears to gate the multi-molecular complex containing the voltagedependent anion channel, defined as mitochondrial permeability transition pore (mPTP) [19] , thus causing a toxic calcium release from the mitochondria [20] . In accordance with this observation, calcium chelating agents are able to reverse paclitaxel-evoked pain [21] , and acetyl-l-carnitine, which prevents mPTP opening [22] , reduces the development of paclitaxel-induced neuropathic pain [23] . Administration of bortezomib leads to intracytoplasmatic vacuolization in dorsal root ganglia (DRG) satellite cells, probably due to mitochondrial and endoplasmic reticulum enlargement [24] . All these intracellular modifications are probably related to the ability of bortezomib to activate mitochondrial-based apoptotic pathways, including activation of caspases [25] and dysregulation of calcium homeostasis [26] . Inhibitors of the mitochondrial electron transport chain (mETC) attenuate mechanical hyperalgesia in both CIPN models and after tumor necrosis factor-(TNF-) treatment [17] . The relevant role of mETC in peripheral pain mechanisms is further corroborated by the effect of inhibitors of adenosine triphosphate (ATP) synthesis to attenuate neuropathic pain [17] . Moreover, it has been demonstrated that the antioxidant agent -lipoic acid, by regulating essential mitochondrial proteins with antioxidant and chaperone properties, exerts neuroprotective effects against chemotherapy-induced neurotoxicity in sensory neurons [27] . Finally, significant changes in the expression of various genes, including those controlling mitochondrial dysfunction associated with vincristine-and bortezomib-evoked peripheral neuropathy, have been demonstrated in humans [25] .
Impaired mitochondrial calcium uptake, or increased leakage of mitochondrial calcium, could exaggerate calcium signals and, eventually, calcium-dependent processes which participate in the neuropathy mechanism. For instance, it has been observed that administration of vincristine and paclitaxel, by raising neuronal calcium levels in the nerves, induces mitochondrial changes, associated with neuronal hyperexcitability [28, 29] . Accordingly, drugs, which reduce intracellular calcium levels are able to reverse the negative effects of altered mitochondrial calcium regulation and neuropathic pain [20, 21] . Furthermore, paclitaxel-and vincristine-evoked neuropathic pain is reduced by both the T-type channel calcium blocker, ethosuximide, and the 2 calcium channel subunit antagonist, gabapentin [30, 31] . In addition, paclitaxel has been reported to increase the expression level of 2 -1 mRNA in the dorsal spinal cord [30, 32] . Accordingly, it has been proposed that 2 -1 subunit in the spinal dorsal horn and DRG is a main site where gabapentin inhibits paclitaxel-induced allodynia [33] . Thus, different lines of evidence indicate that dysregulation of intracellular calcium levels represents an additional factor contributing to the pathogenesis of CIPN.
A number of studies suggest a role of sodium channels in CIPN. Exposure of DRG neurons to oxaliplatin increases sodium currents, which are antagonized by the sodium channel blocker carbamazepine [34] . The oxaliplatin metabolite oxalate probably alters the functional properties of voltagegated sodium channels, resulting in a prolonged open state of the channels and, finally, in the hyperexcitability of sensory neurons [35] . Further, oxaliplatin administration has been described to slow sodium channel inactivation kinetics [1, 34] . A change in sodium channel properties may predispose to ectopic activity, leading to paresthesia and fasciculations [36] . Cold exposure affects sodium channel kinetics [37] and, accordingly, sodium channel dysfunction is aggravated by cold temperatures [38] . Cold hypersensitivity is a typical feature observed in acute oxaliplatin-induced neurotoxicity. It has been shown that acute modulation of sodium channels influences the severity of oxaliplatin-induced neurotoxicity [39, 40] . The involvement of sodium channels is also reported in paclitaxel-induced neuropathic pain, where low doses of tetrodotoxin result able to prevent pain induced by taxane [41] . In contrast with these previous findings, antisense oligodeoxynucleotides targeting the Na v 1.8 channel does not seem to interfere with vincristine-induced neuropathic pain [42] .
An important function of inflammatory mediators has been described in models of CIPN [29, 43] . A recent study demonstrated a correlation between the increase in interleukin 6 (IL-6) and the appearance of bortezomibinduced neuropathic pain [44] . Further, the administration of the prostaglandin E 1 (PGE 1 ) analog, limaprost, attenuated mechanical allodynia induced by paclitaxel and oxaliplatin (but not by vincristine) [32] . An increase in skin Langerhans cells (LC) has been associated with the development of pain in vincristine-and paclitaxel-evoked neuropathy [21] . LC cells may contribute to pain development by different mechanisms including release of nitric oxide (NO) [45] , proinflammatory cytokines [46] , and neurotrophic factors [47] , that in turn cause spontaneous neuronal discharge, nociceptor sensitization, and mechano-hypersensitivity. It has also been demonstrated that paclitaxel-induced neuropathic pain is associated with TNF-and IL-1 induction in lumbar DRGs [48] . Glial cell inhibitors attenuate paclitaxel-and vincristine-induced neuropathic pain [49, 50] , supporting a role for activated glial cells in this condition.
In vincristine-and paclitaxel-evoked neuropathy [21] , and more recently in oxaliplatin-induced neuropathy [51] , a loss of intraepidermal nerve fibers in the plantar hind paw skin region of the sensory neuron peripheral terminal arbors, similar to that documented in other neuropathic pain syn-dromes, has been shown. Neuropathy also seems to be characterized by a loss of the cutaneous A and C fibers (cooland warm-specific) [52] and of A cool-specific fibers, which seem to contribute to cold allodynia [53] . Oxidative stress has been repeatedly proposed to play a central role in the mechanism of CIPN. The effect of antioxidants, including acetyl-l-carnitine, -lipoic acid, and vitamin C, which seem to partially reverse the hyperalgesia, represents indirect proof of the role of oxidative stress in oxaliplatin-induced neuropathy [54, 55] . Recently, administration of the free radicals scavenger, phenyl N-tert-butylnitrone, has been shown to reduce mechanical allodynia in paclitaxel-induced neuropathic pain in rats [56] . Moreover, it has been demonstrated that bortezomib increases ROS in DRG neurons [57] , and that vitamin C or N-acetyl-l-cysteine administration alleviates the cytotoxicity in Schwann cells, but not in myeloma cells treated with bortezomib [58] , thus suggesting that the antioxidant action may selectively afford protection against neurodegeneration without modification of the antineoplastic activity of the chemotherapeutic agent [58] .
Recent evidence also supports the role of other biological effectors in CIPN. For instance, paclitaxel-induced peripheral neuropathy is characterized by the activation of calciumactivated proteases, such as calpains and caspases [17, 59] , or mitogen activated protein kinase (MAPK). Furthermore, prolonged exposure to oxaliplatin induces early activation of p38 and extracellular signal-regulated kinase 1/2 (ERK1/2) MAPKs in DRG neurons, eventually provoking neuronal apoptosis. Contrasting data have been reported on the role of neuropeptides, such as calcitonin gene related peptide (CGRP) or substance P (SP) [60] [61] [62] . The role of NO has also been evaluated, and there is indication that NO contributes to vincristine-and oxaliplatin-induced neuropathy. Finally, a number of other mediators or effector mechanisms have been implicated in the genesis of CIPN, including Nmethyl-D-aspartate (NMDA) and 5-hydroxytryptamine (5HT) receptors, potassium channels, protein kinase C (PKC) or l-serine (see for review [63] ).
Recently, in addition to classical calcium or sodium channels, remarkable interest has been paid to a possible role in CIPN of the additional channels preferentially located in sensory neuronal membranes. In particular, research on transient receptor potential (TRP) channels seems to represent a promising area of investigation, as emerging and compelling data have shown the contribution of several members of this channel family to the mechanism of CIPN.
TRP CHANNELS IN PRIMARY SENSORY NEU-RONS: ROLE IN PAIN TRASMISSION
Neuropathic pain is characterized by hypersensitivity to mechanical, thermal and/or chemical stimuli, elicited by exogenous, or endogenous causes, including trauma, neurotoxins, infections, heredity, immunological and metabolic diseases, and other conditions. A variety of molecular mechanisms have been advocated as underlying pathways contributing to pain hypersensitivity. In particular, activation and sensitization of nociceptors have been considered as an initial mechanism that eventually results in neuronal hypersensitivity. The subpopulation of primary sensory neurons encompasses highly heterogeneous subgroups of neurons. In addition to morphological, electrophysiological, and functional criteria, primary sensory neurons may be distinguished according to the expression of neuropeptides, namely the tachykinins SP and the neurokinin A, and CGRP, which upon release from peripheral nerve endings mediate neurogenic inflammation [64, 65] . Indeed, the first description of the ability of a subset of sensory neurons to orchestrate an early inflammatory response, mainly represented by arteriolar vasodilatation, was reported by Bayliss [66] , and subsequently by Sir Thomas Lewis [67] , who defined in detail the dual "nocifensor" role of this type of neuron.
Nociceptors that release neuropeptides, thus contributing to neurogenic inflammation, are known to express some TRP channels, which, among other features, are sensitive to changes in temperature and therefore defined also as thermoTRPs [68] . About 15 years after the cloning of the vanilloid 1 channel (TRPV1, the so called 'capsaicin receptor'), additional members of the TRP family have been found to be expressed by nociceptors [69] . These include the vanilloid 2 (TRPV2), 3 (TRPV3), and 4 (TRPV4) channels, the TRPM8 (the 'menthol receptor'), and the ankyrin 1 (TRPA1) channels. These channels are transducers of an unprecedented series of chemical, thermal, and mechanical stimuli that are usually known to induce pain. Although the hallmark of TRP channels is their "polymodality", TRPV1, TRPV3, TRPM8, and TRPA1 have also been recognized as chemoreceptors, rather selectively responsive to capsaicin, camphor [70] , menthol [71, 72] , and mustard oil [73] , respectively. The reader is referred to other reviews for detailed descriptions of the specific thermal, mechanical, and chemical sensitivity of TRP channels expressed by nociceptors [65, 68] .
THE ROLE OF TRP CHANNELS IN CHEMOTHERA-PY-INDUCED PERIPHERAL NEUROPATHY
Pharmacological and genetic studies using animal models of CIPN induced by various chemotherapeutic agents indicate that the mechanisms underlying mechanical and thermal hyperalgesia are multiple. Notwithstanding, recent evidence has emphasized a primary role for members of the TRP family, in particular TRPV1, TRPV4, TRPA1, and TRPM8, in the mechanical and thermal hypersensitivity evoked by chemotherapeutic agents in rodents [62, 74, 75] .
TRPV1
The invertebrate relatives of TRPV1 are essential to sensory transduction (phototransduction, thermosensation, mechanosensation, osmosensation) [76] , while in mammals TRPV1 seems to contribute to hypersensitivity to thermal, chemical, and mechanical stimuli associated with peripheral inflammation and neuronal damage. A specific feature of TRPV1 relies on its ability, following intense and prolonged activation, to induce neuronal desensitization [77, 78] . TRPV1 is activated by noxious heat (43-52 °C), and its activation by capsaicin results in heat hypersensitivity [79] . Among various adverse reactions, heat hypersensitivity has been often reported by patients treated with platinum-based anticancer drugs [80] . Thus, the hypothesis that TRPV1 plays a role in such reactions has been advanced. Treatment with cisplatin has been found to produce upregulation of TRPV1 mRNA in cultured DRG neurons [81] . A similar upregulation occurs also after in vivo treatment with cisplatin, although cisplatin-treated mice showed no change in the proportion of TRPV1-immunopositive trigeminal ganglia (TG) neurons [82] . TRPV1 upregulation was associated with increased nociceptors responsiveness and contributed to cisplatin-evoked thermal, but not mechanical, hyperalgesia in mice [82] . In addition, acute exposure to oxaliplatin induced TRPV1 sensitization, which may cause neuronal damage [81] . The mechanism through which oxaliplatin/cisplatininduced neuropathy results in TRPV1 sensitization is unclear. However, enhanced TRPV1 protein trafficking, consequent upon mRNA overexpression, to peripheral nerve processes, or channel phosphorylation by different kinases, leading to enhanced TRPV1 sensitivity, have been proposed as a general mechanism contributing to pathological pain states [83] .
TRPV4
TRPV4 channel is a polymodal receptor with a wide expression pattern and a corresponding variety of possible pathophysiological roles [84] . TRPV4 is expressed in different neuronal and non-neuronal cells, including urinary bladder, kidney, vascular endothelium, keratinocytes, cochlear hair cells, and Merkel cells [85] [86] [87] . Likewise the TRPV1 channel, TRPV4 activation on TG or DRG neurons [84, 88] causes SP and CGRP release, thus evoking neurogenic inflammation in peripheral tissues [89] . TRPV4 was firstly identified as an osmo-transducer activated by decrease in osmolarity, suggesting a role in the regulation of cell swelling [84, 90] . Later studies demonstrated that TRPV4 is activated by shear stress [91] , innocuous warmth (27 -35 °C) [88, 92] , low pH, citrate [87] , endocannabinoids and arachidonic acid metabolites [92, 93] , NO [94] , and synthetic selective agonists, such as the phorbol ester 4 -phorbol 12,13-didecanoate (4 -PDD) [95] .
The mechanosensitive nature of TRPV4 and its implication in sensing shear stress suggest a role in flow-sensitive cells, such as vascular endothelial and renal tubular epithelial cells. The mechanism through which TRPV4 is activated by mechanical stress is still under debate. Two transduction pathways have been proposed to regulate TRPV4 activation: the phospholipase (PL) C (PLC)/diacylglycerol (DAG) pathway and the PLA 2 /arachidonic acid (AA) pathway [96, 97] . Some evidence suggests that activation of TRPV4 by hypotonicity involves its phosphorylation by the Src family of tyrosine kinase [98] . Although the molecular mechanism of hypotonicity-induced TRPV4 activation should be further investigated, studies addressing the gating mechanism of the channel by cell swelling exclude that it is directly gated by mechanotransduction since it does not respond to membrane stretch [90] .
It has been shown that hypotonicity becomes painful to the animals when nociceptive fibers are sensitized by the PGE 2 , whose levels increase during inflammation or in response to mechanical, chemical, and thermal injury. TRPV4 also plays a crucial role in mechanical hyperalgesia elicited by exposure to inflammatory mediators. Indeed, PGE 2 and serotonin can act synergistically through cAMP/protein kinase (PK) A (PKA) and PKC to engage TRPV4 in hyperalgesia to mechanical and osmotic stimuli [99] . In addition, protease-activated receptor 2 (PAR 2 ) agonists may sensitize TRPV4 through the activation of multiple second messenger pathways, such as PKA, PKC, PKD, and PLC [89] . Proteases generated during inflammation activate PAR 2, thus leading to TRPV4-mediated release of SP and CGRP in the spinal cord and TRPV4-induced mechanical hyperalgesia [100] .
Recent evidence has proposed a role for TRPV4 in mechanical allodynia in rodent models of CIPN [101] [102] [103] . In different models of painful peripheral neuropathy, mechanical hyperalgesia was markedly reduced by spinal intrathecal administration of oligodeoxynucleotides antisense to TRPV4 [74] . TRPV4 knock-out mice showed reduced mechanical hyperalgesia induced by the anticancer drugs, paclitaxel and vincristine, or in a diabetic model [74] . TRPV4 plays a major role in mechanical hyperalgesia, and also contributes to enhanced nociception to hypo-osmotic stimuli in paclitaxeltreated rats. TRPV4-mediated hypersensitivity by paclitaxel is not attributable to increased mRNA levels, but rather it may be related to a specific interaction with second messenger pathways [101] . Similarly to paclitaxel, treatment with vincristine has been reported to produce mechanical allodynia in rodents through a TRPV4-dependent mechanism [74] . Authors suggest that TRPV4 is not directly activated by these agents, but plays a role in mechanotransduction, as a component of a molecular complex that functions only in presence of inflammation or nerve injury phenomena. This complex pathway results in the activation of a signaling cascade initiated by integrins which, via Src tyrosine kinase, induces membrane insertion and/or activation of the TRPV4 channel in sensory neurons. Tyrosine kinases are known to regulate trafficking of ion channels and receptors. Recent reports demonstrate that Src tyrosine kinases participate in the modulation of TRP channel function [98, 104, 105] , and this mechanism could be responsible for TRPV4 sensitization. In paclitaxel-induced peripheral neuropathy TRPV4-mediated mechanical hyperalgesia results essentially dependent on integrin/Src tyrosine kinase signaling [101] .
Another recent paper demonstrates that paclitaxel may release mast cell tryptase, which activates PAR 2 receptors expressed in primary sensory neurons [100] . PAR 2 activation and the downstream enzymes, PKA, PKC , and PLC, cause sensitization of TRPV1, TRPV4, and TRPA1, thereby leading to mechanical allodynia and thermal hyperalgesia. Targeting the signaling pathways of PAR 2 seems to effectively attenuate paclitaxel-induced mechanical, heat, or cold hypersensitivity [100] . The contribution of TRPV4 to CIPN, and more in general to models of inflammatory pain, corroborates the hypothesis that TRPV4 plays a role in sensitization of nociceptors and makes it a novel target for the development of an innovative class of analgesics.
TRPA1
TRPA1, originally cloned from human fetal lung fibroblasts, is a nonspecific calcium-permeable cationic channel expressed in primary sensory neurons of the DRG, TG and vagal ganglia (VG), where it co-localizes with the TRPV1 channel. TRPA1 is also widely expressed in many cell types, tissues and organs, including hair cells, pancreas, heart, brain, keratinocytes [106] , urinary bladder [107] , prostate [108] , arteries [109] , enterochromaffin cells [110] , odontoblasts [111] , dental pulp [112] , synovial fibroblasts [113] , airway epithelial [114] , and smooth muscle cells [156] . Transient receptor potential ankyrin 1 channel localized to non-neuronal airway cells promotes non-neurogenic inflammation.
It has been proposed that TRPA1 functions as a detector of mechanical stimuli and noxious cold (<17 °C), although this hypothesis is still controversial. Altered mechanical thresholds observed in TRPA1 knock-out mice [115] and interaction between TRPA1 N-terminal ankyrin repeat domain and other proteins, such as cadherin [116] , suggested that TRPA1 is involved in mechano-sensation. However, other data failed to find any connection between TRPA1 activation and mechanosensation [117] . Similarly, whether or not TRPA1 functions as a sensor of noxious cold remains an unresolved question. Several studies demonstrated that noxious cold activates TRPA1 channels, both directly [118] [119] [120] and indirectly [121] . However, negative results were obtained in mouse TRPA1 channels heterologously expressed in human embryonic kidney cells [122] , and neuronal activation by cold temperatures was found to be similar between wild-type and TRPA1 knock-out mice [123] . In addition, in vivo studies employing two independently produced TRPA1 knock-out mice breeds yield conflicting results, leaving the controversy unsettled [115, 117, 120] . More recently, it has been proposed that noxious cold activates TRPA1 [124] , but with less potency than allyl isothiocyanate. Moreover, it has been shown that cold stimuli potentiated TRPA1 activation induced by allyl isothiocyanate [124] .
Whereas the role of TRPA1 in mechano-and coldtransduction remains to be clarified, it has been extensively demonstrated that TRPA1 plays a major role in chemosensation. In fact, TRPA1 is activated by a wide range of pungent and irritant compounds [125] , including ingredients of various spicy foods, such as allyl isothiocyanate (mustard oil, wasabi and horseradish) [73] , allicin and diallyldisulfide (garlic derivatives) [126] , cinnamaldehyde (cinnamon), and environmental irritants and industry pollutants, such as acetaldehyde [127] , formalin [128] , hypochlorite, isocyanates [129] , ozone [130] , carbon dioxide [131] , and acrolein [117] , a highly reactive , -unsaturated aldehyde present in tear gas, and cigarette smoke [132] . Moreover, isofluorane [133] , nicotine [134] , NO donors [135] , and cyclophosphamide [117] have been reported to activate TRPA1.
In addition to exogenous compounds, endogenous molecules have been identified as TRPA1 agonists. Compelling evidence indicates that TRPA1 is gated by an unprecedented series of endogenous agents generated at sites of inflammation and tissue injury. The product of fatty acid metabolism, 15-deoxy-delta-12,14-prostaglandin J2 (15d-PGJ 2 ), which is synthesized by cyclooxygenases after an initial inflammatory signal, is a potent activator of TRPA1 [136, 137] . The cyclopentenone isoprostane 8-iso-PGA2 is also capable of targeting TRPA1 [137] . Oxidative decomposition of polyunsaturated fatty acids, such as linoleic and arachidonic acid, leads to the formation of a host of reactive carbonyl species that may target TRPA1. These products include , -unsaturated aldehydes acrolein, 4-hydroxy-2-nonenal (HNE) [138] , and 4-oxononenal [139] . Moreover, reactive nitrogen species (RNS) such as peroxynitrite and nitrooleic acid [130] and ROS, such as oxygen peroxide and hydrogen peroxide [140] , target TRPA1. Thus, oxidative stress produced by neutrophilic and macrophagic activation at sites of inflammation generates molecules that activate TRPA1 leading to pain and neurogenic inflammation. These findings suggest that TRPA1 plays a key role in sensing tissue damage and nociceptive signaling. TRPA1 channel can be gated by distinct mechanisms. Most of TRPA1 activators are characterized by the presence of a highly reactive electrophilic group that, via a Michael-addition reaction, form covalent bonds with nucleophilic groups, such as cysteine and lysine residues located in the N-terminal cytoplasmic domain of the channel, hence inducing modifications of TRPA1 N-terminal that lead to dilation of the channel permeation pore [141, 142] . As in the case of electrophilic agonists, HNE provokes TRPA1 gating by covalent modification of cysteine and lysine residues located within the N-terminal cytoplasmic domain of the channel [138] . Unlike these molecular species, it has been reported that H 2 O 2 activates TRPA1 via disulfide bond formation induced by oxidation [143] .
In addition to direct channel activation, different inflammatory agents that target G protein coupled receptors (e.g., bradykinin) and tyrosine kinases receptors (e.g., nerve growth factor) can indirectly sensitize TRPA1 by activating PKA or PKC [125] . Similar mechanisms of TRPA1 sensitization have been reported to occur by PAR 2 agonists, probably by activation of PLC, which releases the inhibition of TRPA1 from plasma membrane PIP 2 [144] . This evidence suggests that TRPA1 functions as an integrator of different inflammatory mediators, in turn leading to amplification of inflammatory and nociceptive signals.
Patients treated with several anticancer drugs develop hypersensitivity to cold stimuli, thus suggesting the involvement of TRPA1 in this adverse reaction. In addition, induction of oxidative stress is a general mechanism that may contribute to the antineoplastic effect of several chemotherapeutic agents [145] , and the TRPA1 channel is a sensor of oxidative stress byproducts [140] . Thus, due to its localization on nociceptive sensory neurons, and being a major thermal and oxidative stress target, the TRPA1 receptor seems to be perfectly suited to contribute to symptoms of CIPN.
Recently, our research group has disclosed the role of TRPA1 in models of CIPN [103, 146] . By both genetic and pharmacological approaches, we showed that TRPA1 entirely mediates mechanical and cold hypersensitivity induced by oxaliplatin and cisplatin [146] in mice and rats. We confirmed [103] that TRPV4 mediates part of the mechanical hyperalgesia induced by paclitaxel [74] , and we showed that TRPV4-resistant mechanical hyperalgesia was exclusively mediated by TRPA1 [103] . We also discovered that paclitaxel-induced cold allodynia was completely due to TRPA1 activation [103] . One final common pathway activated by the otherwise chemically heterogeneous group of molecules, such as chemotherapeutic agents, is the production of oxidative stress in different tissues and cells [147, 148] and, through this effect they can potentially activate and/or sensitize the TRPA1 channel. Our recent works [103, 146] , however, indicated that oxaliplatin and paclitaxel do not directly gate TRPA1, as they do not cause any calcium response in primary culture of mouse or rat DRG neurons. However, Chinese hamster ovary (CHO) cells transfected with the mouse TRPA1 channel respond, with a glutathionesensitive intracellular calcium mobilization, upon challenge with oxaliplatin, whereas untransfected CHO cells do not. Thus, we hypothesized that calcium response by oxaliplatin requires two conditions. The first is that the cell expresses TRPA1, and the second is that the cell may generate sufficient levels of oxidative stress. It is possible that neurons do not produce sufficient oxidative stress to activate TRPA1, whereas CHO cells possess the metabolic and enzymatic repertoire to produce high enough ROS levels which, when the cells express the recombinant TRPA1, are sufficient to gate the channel. In the case of sensory neurons neighboring cells to nerve terminals may release oxidative stress byproducts generated by paclitaxel, hence gating TRPA1. Paclitaxel seems to utilize the same pathway given that the TRPA1-dependent CGRP release evoked by the drug was completely abated in the presence of glutathione [103] . Similarly to what has been found under inflammatory circumstances [149] , platinum-based drugs also increase TRPA1 expression in DRG [82] . However, in this study, appropriate functional experiments that could corroborate the intriguing molecular data were not performed.
Moreover, in a rat model of diabetes, paclitaxel significantly enhanced cold hyperalgesia in comparison to normoglycemic paclitaxel-treated control animals [149] . These effects were prevented by the ROS scavenger, N-acetylcysteine, and by the selective TRPA1 antagonist, HC-030031 [128] . In diabetic and control rats, paclitaxel treatment was associated with an accumulation of atypical mitochondria and an increase in mitochondrial ROS production [149] . Paclitaxel potentiation of cold hyperalgesia in diabetes may result from the combination of increased mitochondrial ROS production and poor radical detoxification induced by paclitaxel treatment and increased TRPA1 expression [149] .
TRPM8
TRPM8 is expressed by a non-peptidergic subpopulation of nociceptors and responds to mild and noxious cold (<25 °C) temperatures. TRPM8, together with TRPA1, seems to mediate hypersensitivity to cold stimuli [71] . An increase in TRPM8 expression occurs in some sensory neurons after nerve injury [150] , possibly contributing to enhanced cooling sensation. Similarly, oxaliplatin increased the expression of TRPM8 mRNA in mouse DRG neurons when cold hypersensitivity peaked, suggesting that cold hypersensitivity is, at least partly, due to the increased expression of TRPM8 in primary sensory neurons [151] . In addition, wet-dog shake and jumping behaviors elicited by icilin, a non selective TRPM8 activator, were significantly increased in mice treated with oxaliplatin [151] . Oxaliplatin seems to affect TRPA1 rather than TRPM8, because oxaliplatin-treatment induces sensitization to icilin, which also activates TRPA1 expressing neurons, but not the response to a TRPM8 selective ligand, WS12 [81] . A recent paper reported a possible contribution of TRPM8 expressing fibers to cold hypersensitivity induced by oxaliplatin [152] . Paradoxically, a case report showed the analgesic effect of topical menthol application in CIPN induced by bortezomib [153] . In addition, topical application of menthol was able to significantly reverse CIPN induced by carboplatin, and its prolonged application during chemotherapy appeared to prevent neuropathy worsening [154] . More basic and clinical investigations are clearly required to clarify the role of TRPM8 in CIPN.
CONCLUSION
CIPN encompasses a large variety of symptoms, but neuropathic pain represents a prominent and dose-limiting manifestation for many patients. Although a series of hypotheses has been reported to explain this painful condition, the mechanism underlying CIPN remains unknown, and the disease remains undertreated, the main undesired consequence being therapy discontinuation. However, over the past two years a series of mechanisms and potential targets through which anticancer drugs may induce peripheral neuropathy emerged.
In particular, recent acquisitions on members of the TRP family, such as TRPV1, TRPV4, TRPA1, and TRPM8, expressed by primary nociceptors, indicate that these channels play a major role in models of CIPN. Emerging data show that oxidative stress produced by chemotherapeutic agents initiates channel gating, and this phenomenon seems to be specifically important for TRPA1 activation and sensitization.
However, several questions regarding the relationship between CIPN and TRP channels remain unanswered. Upregulation of TRP channels has been claimed as a possible mechanism for protracted sensory neuropathy, but this phenomenon has not been always demonstrated. It is highly possible that additional molecular mechanisms are involved in TRP hyperactivity, including altered intracellular transduction pathways and/or epigenetic factors, which have been previously proposed to play a key role in models of inflammatory and neuropathic pain [69, 83, 155] . Thus, further studies are required to identify the upstream and downstream events concerning the primary sensory neurons, which are associated to chemotherapeutic agent-evoked and TRPmediated hypersensitivity, and ultimately to CIPN.
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